Cost analysis of the management of end-stage renal disease patients in Abuja, Nigeria

Although the treatment for end-stage renal disease (ESRD) under Nigeria's National Health Insurance Authority is haemodialysis (HD), the cost of managing ESRD is understudied in Nigeria. Therefore, this study estimated the provider and patient direct costs of haemodialysis and managing ESRD in...

Full description

Saved in:

Bibliographic Details
Published in:	Cost effectiveness and resource allocation 2023-12, Vol.21 (1), p.94-94, Article 94
Main Authors:	Agada-Amade, Yakubu Adole, Ogbuabor, Daniel Chukwuemeka, Eboreime, Ejemai, Onwujekwe, Obinna Emmanuel
Format:	Article
Language:	eng
Subjects:	Chronic illnesses Chronic kidney failure Costs Cross-sectional studies Economic evaluation End-stage renal Disease GNP Gross National Product Haemodialysis Health care expenditures Health facilities Hemodialysis High-definition television Hospitals Insurance coverage Kidney diseases Medical research Medically uninsured persons Medicine, Experimental National health insurance Nephrology Nigeria Patients Public private partnerships Questionnaires Sample size Surveys
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Although the treatment for end-stage renal disease (ESRD) under Nigeria's National Health Insurance Authority is haemodialysis (HD), the cost of managing ESRD is understudied in Nigeria. Therefore, this study estimated the provider and patient direct costs of haemodialysis and managing ESRD in Abuja, Nigeria. The study was a cross-sectional survey from both healthcare provider and consumer perspectives. We collected data from public and private tertiary hospitals (n = 6) and ESRD patients (n = 230) receiving haemodialysis in the selected hospitals. We estimated the direct providers' costs using fixed and variable costs. Patients' direct costs included drugs, laboratory services, transportation, feeding, and comorbidities. Additionally, data on the sociodemographic and clinical characteristics of patients were collected. The costs were summarized in descriptive statistics using means and percentages. A generalized linear model (gamma with log link) was used to predict the patient characteristics associated with patients' cost of haemodialysis. The mean direct cost of haemodialysis was $152.20 per session (providers: $123.69; and patients: $28.51) and $23,742.96 annually (providers: $19,295.64; and patients: $4,447.32). Additionally, patients spent an average of $2,968.23 managing comorbidities. The drivers of providers' haemodialysis costs were personnel and supplies. Residing in other towns (HD:β = 0.55, ρ = 0.001; ESRD:β = 0.59, ρ = 0.004), lacking health insurance (HD:β = 0.24, ρ = 0.038), attending private health facility (HD:β = 0.46, ρ
ISSN:	1478-7547 1478-7547